小剂量递增服用厄贝沙坦防治肝硬化门脉高压的临床研究

Taking a small dose escalation he sand prevention and treatment of liver cirrhosis portal hypertension's clinical research

目的研究厄贝沙坦小剂量递服对于肝硬化门脉高压的防治效果。方法根据随机原则,将2014年7月—2015年11月我院收治的高危肝硬化门脉高压患者120例分为三组,分别予以厄贝沙坦治疗(实验组)、普萘洛尔治疗(对照组)、厄贝沙坦+普萘洛尔治疗(联合组),每组40例,对比两组临床效果。结果与对照组相比,实验组和联合组的面积比均相对更低;实验组和联合组的PRA、AII、心率、舒张压及收缩压均相对更低,且联合组的各项指标水平较实验组下降显著(P<0.05)。结论厄贝沙坦小剂量递增防治肝硬化门脉高压的效果显著,利于改善肝脏胶原沉积现象,促进血液相关指标的改善,具推广意义。

Objective ： To study the he sand temple small doses of reeursive suit for liver cirrhosis portal hypertension prevention and cure effect. Methods ： 120 cases of patients with high risk of cirrhotic portal hypertension at the Hospital in July 2014 - in November 2015 were divided into three groups, be he sand treatment （experimental group） , propranolol treatment （ control group） , temple he sand ＋ propranolol treatment group （joint） v respectively, with 40 cases in each group, and the clinical effect was compared between the two groups. Results： Compared with control group, experimental group and the combined group than the area are relatively low; Experimental group and the joint group of PRA, AII, heart rate, diastolic blood pressure and systolic blood pressure were relatively lower, and the indicators of joint group level reduced significantly com- pared with the experimental group （P 〈 0.05 ）. Conclusion ： He sand templesmall dose escalation effect is remarkable for the prevention and control of cirrhotic portal hypertension, improves liver collagen deposition and promotes the improvement of the related parameters of the blood.